Home » Stocks » Xeris Pharmaceuticals

Xeris Pharmaceuticals, Inc. (XERS)

Stock Price: $2.79 USD 0.06 (2.20%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 125.54M
Revenue (ttm) 4.26M
Net Income (ttm) -129.49M
Shares Out 37.59M
EPS (ttm) -4.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $2.79
Previous Close $2.73
Change ($) 0.06
Change (%) 2.20%
Day's Open 2.91
Day's Range 2.60 - 3.10
Day's Volume 13,110,759
52-Week Range 1.42 - 12.94

More Stats

Market Cap 125.54M
Enterprise Value 87.08M
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 37.59M
Float 22.99M
EPS (basic) -4.62
EPS (diluted) -4.56
FCF / Share -3.45
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.39M
Short Ratio 2.63
Short % of Float 3.76%
Beta 2.11
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 29.46
PB Ratio 7.69
Revenue 4.26M
Operating Income -125.20M
Net Income -129.49M
Free Cash Flow -113.07M
Net Cash 38.46M
Net Cash / Share 0.85
Gross Margin 26.26%
Operating Margin -2,937.52%
Profit Margin -3,038.20%
FCF Margin -2,652.98%
ROA -56.41%
ROE -193.02%
ROIC -115.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(337.28% upside)
Current: 2.79
Target: 12.20
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth12.34%55.72%44.74%-
Gross Profit1.122.421.551.07
Operating Income-122-59.34-26.63-13.23
Net Income-126-60.08-26.55-13.21
Shares Outstanding26.1112.052.031.84
Earnings Per Share-4.81-4.99-13.09-7.17
Operating Cash Flow-104-56.28-24.66-16.09
Capital Expenditures-1.11-1.51-0.70-0.04
Free Cash Flow-105-57.79-25.36-16.12
Cash & Equivalents75.5511342.0532.27
Total Debt58.3131.89--
Net Cash / Debt17.2480.7442.0532.27
Book Value14.4475.41-57.83-31.93
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Xeris Pharmaceuticals, Inc.
Country United States
Employees 199
CEO Paul R. Edick

Stock Information

Ticker Symbol XERS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XERS
IPO Date June 21, 2018


Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that is in Phase II clinical trials for the treatment of congenital hyperinsulinism, post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, and hypoglycemia-associated autonomic failure, as well as for treating hypoglycemia associated with intermittent and chronic conditions, and bi-hormonal artificial pancreas closed-loop systems. In addition, it develops continuous subcutaneous glucagon infusion system of ready-to-use glucagon; ready-to-use diazepam formulation, which is in Phase I clinical trial for the treatment of acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is in pre-clinical stage for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.